Future Potential of Adagrasib/Cetuximab in KRAS G12C Mutant CRC

Dr. Scott Kopetz from The University of Texas MD Anderson Cancer Center recently discussed the exciting results from the evaluation of adagrasib (Krazati) in combination with cetuximab (Erbitux) for patients with locally advanced or metastatic colorectal cancer (mCRC) harboring KRAS G12C mutations.

The potential FDA approval of this treatment marks a significant advancement in patient care, with the treatment already included in the National Comprehensive Cancer Network Guidelines for colon cancer. Oncologists are hopeful that this approval will make the treatment more accessible to a wider range of patients. Dr. Kopetz anticipates that with FDA approval, Adagrasib plus cetuximab will become a standard treatment option for patients.

The results from studies on a heavily pretreated patient population are promising, showing a 34% objective response rate, a median progression-free survival of 6.9 months, and a median overall survival of 15.9 months. Dr. Kopetz believes that these findings suggest the potential for exploring this regimen in earlier lines of therapy. The phase 3 KRYSTAL-10 study of adagrasib plus cetuximab in the second-line KRAS G12C–mutated CRC setting has completed enrollment and the results are highly anticipated.

The ongoing research into treatment options for patients with KRAS G12C–mutated CRC is providing optimism for a new therapeutic approach. The completion of the KRYSTAL-10 study will offer valuable insights into the role of adagrasib plus cetuximab in the treatment sequence for CRC, potentially shaping future treatment guidelines and clinical practices.